Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Onconova Therapeutics, Inc. | a2231491zex-32_1.htm |
| EX-31.2 - EX-31.2 - Onconova Therapeutics, Inc. | a2231491zex-31_2.htm |
| EX-31.1 - EX-31.1 - Onconova Therapeutics, Inc. | a2231491zex-31_1.htm |
| EX-23.1 - EX-23.1 - Onconova Therapeutics, Inc. | a2231491zex-23_1.htm |
| EX-21.1 - EX-21.1 - Onconova Therapeutics, Inc. | a2231491zex-21_1.htm |
| EX-10.27 - EX-10.27 - Onconova Therapeutics, Inc. | a2231491zex-10_27.htm |
| 10-K - 10-K - Onconova Therapeutics, Inc. | a2231491z10-k.htm |
QuickLinks -- Click here to rapidly navigate through this document
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Onconova Therapeutics, Inc. (the "Company") for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Mark Guerin, Chief Financial Officer, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, based on my knowledge:
- (1)
- The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2)
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ MARK GUERIN Mark Guerin Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
Dated: March 29, 2017
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002